Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin

Bone

Volumn 39, Issue 4, 2006, Pages 773-786

  Rowe, Peter S N ^a   Matsumoto, Naoko ^b,c   Jo, Oak D ^b,c   Shih, Remi N J ^b,c   Oconnor, Jeannine ^b,c   Roudier, Martine P ^e   Bain, Steve ^e   Liu, Shiguang ^a   Harrison, Jody ^d   Yanagawa, Norimoto ^b,c  

^a Kidney Institute   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e SkeleTech Inc   (United States)

Author keywords

FGF23; MEPE; Mineralization; Osteomalacia; PHEX; Rickets

Indexed keywords

ALKALINE PHOSPHATASE; CA 074; FIBROBLAST GROWTH FACTOR 23; METALLOPROTEINASE; METHIONYLGLUTAMYLPROLYLGLUTAMIC ACID; PEPSTATIN; PEPTIDE; PROTEINASE INHIBITOR; SERYLALANYLARGINYLMETHIONINE; UNCLASSIFIED DRUG; VITAMIN D;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEFECT; BONE GROWTH; BONE MINERALIZATION; CONTROLLED STUDY; CORTICAL BONE; EXTRACELLULAR MATRIX; FEMUR; GROWTH PLATE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOMALACIA; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN MOTIF; SPECIES COMPARISON; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM; VITAMIN D RESISTANT RICKETS;

ANIMALS; CALCIFICATION, PHYSIOLOGIC; CATHEPSIN B; CATHEPSIN D; EXTRACELLULAR MATRIX PROTEINS; FEMUR; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MODELS, BIOLOGICAL; OSTEOBLASTS; PEPSTATINS; PROTEASE INHIBITORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33748376254     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.04.012     Document Type: Article

References (88)

1. Argiro L., Desbarats M., Glorieux F.H., and Ecarot B. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics 74 (2001) 342-351
2. Bai X., Miao D., Panda D., Grady S., McKee M.D., Goltzman D., et al. Partial rescue of the hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol. Endocrinol. 16 (2002) 2913-2925
3. Bai X.Y., Miao D., Goltzman D., and Karaplis A.C. The autosomal dominant hypophosphatemic rickets R176Q mutation in FGF23 resists proteolytic cleavage and enhances in vivo biological potency. J. Biol. Chem. 278 (2003) 9843-9849
4. Bain S.D., Impeduglia T.M., Rubin C.T., Rubin C.T., Gross T.S., McLeod K.J., et al. Cement line staining in undecalcified thin sections of cortical bone. Stain Technol. 65 (1990) 1-5
5. Beck L., Karaplis A.C., Amizuka N., Hewson A.S., Ozawa H., and Tenenhouse H.S. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 5372-5377
6. Berndt T., Craig T.A., Bowe A.E., Vassiliadis J., Reczek D., Finnegan R., et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J. Clin. Invest. 112 (2003) 785-794
7. Bresler D., Bruder J., Mohnike K.L., Fraser D., and Rowe P.S.N. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J. Endocrinol. 183 (2004) R1-R9
8. Carpenter T.O. New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. Pediatr. Clin. North Am. 44 (1997) 443-466
9. Carpenter T.O., Ellis B.K., Insogna K.L., Philbrick W.M., Sterpka J., and Shimkets R. FGF7-An inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J. Clin. Endocrinol. Metab. 90 (2005) 1012-1020
10. Carpenter T.O., and Gundberg C.M. Osteocalcin abnormalities in Hyp mice reflect altered genetic expression and are not due to altered clearance, affinity for mineral, or ambient phosphorus levels. Endocrinology 137 (1996) 5213-5219
11. Carpenter T.O., Keller M., Schwartz D., Mitnick M., Smith C., Ellison A., et al. 24,25 Dihydroxyvitamin D supplementation corrects hyperparathyroidism and improves skeletal abnormalities in X-linked hypophosphatemic rickets-A clinical research center study. J. Clin. Endocrinol. Metab. 81 (1996) 2381-2388
12. Carpenter T.O., Moltz K.C., Ellis B., Andreoli M., McCarthy T.L., Centrella M., et al. Osteocalcin production in primary osteoblast cultures derived from normal and Hyp mice. Endocrinology 139 (1998) 35-43
13. Chau H., El-Maadawy S., McKee M.D., and Tenenhouse H.S. Renal calcification in mice homozygous for the disrupted type IIa Na/Pi cotransporter gene Npt2. J. Bone Miner. Res. 18 (2003) 644-657
14. Capparelli A.W., Roh D., Dhiman J.K., Jo O.D., and Yanagawa N. Altered proximal tubule glucose metabolism in X-linked hypophosphatemic mice. Endocrinology 130 (1992) 328-334
15. Davidai G.A., Nesbitt T., and Drezner M.K. Variable phosphate-mediated regulation of vitamin D metabolism in the murine hypophosphatemic rachitic/osteomalacic disorders. Endocrinology 128 (1991) 1270-1276
16. De Beur S.M., Finnegan R.B., Vassiliadis J., Cook B., Barberio D., Estes S., et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J. Bone Miner. Res. 17 (2002) 1102-1110
17. Dobbie H., Shirley D.G., Faria N.J., Rowe P.S.N., Slater J.M., and Unwin R.J. Infusion of the bone-derived protein MEPE causes phosphaturia in rats (Abstract). J. Am. Soc. Nephrol. 14 (2003) 468A
18. M.K. Drezner, PHEX gene and hypophosphatemia. Kidney Int. 2000.Jan.;57.(1.):9.-18. 57:9-18; 2000.
19. Drezner M.K. The role of abnormal vitamin D metabolism in X-linked hypophosphatemic rickets and osteomalacia. Adv. Exp. Med. Biol. 178 (1984) 399-404
20. Drezner M.K., Lyles K.W., Haussler M.R., and Harrelson J.M. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia. J. Clin. Invest. 66 (1980) 1020-1032
21. Dubois S.G., Ruchon A.F., Delalandre A., Boileau G., and Lajeunesse D. Role of abnormal neutral endopeptidase-like activities in Hyp mouse bone cells in renal phosphate transport. Am. J. Physiol. Cell Physiol. 283 (2002) C1414-C1421
22. Ecarot-Charrier B., Glorieux F.H., Travers R., Desbarats M., Bouchard F., and Hinek A. Defective bone formation by transplanted Hyp mouse bone cells into normal mice. Endocrinology 123 (1988) 768-773
23. Ecarot B., Caverzasio J., Desbarats M., Bonjour J.P., and Glorieux F.H. Phosphate transport by osteoblasts from X-linked hypophosphatemic mice. Am. J. Physiol. 266 (1994) E33-E38
24. Ecarot B., Glorieux F.H., Desbarats M., Travers R., and Labelle L. Defective bone formation by Hyp mouse bone cells transplanted into normal mice: evidence in favor of an intrinsic osteoblast defect. J. Bone Miner. Res. 7 (1992) 215-220
25. Ecarot B., Glorieux F.H., Desbarats M., Travers R., and Labelle L. Effect of 1,25-dihydroxyvitamin D3 treatment on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice. J. Bone Miner. Res. 10 (1995) 424-431
26. Ecarot F.H., Glorieux F.H., Desbarats M., Travers R., and Labelle L. Effect of dietary phosphate deprivation and supplementation of recipient mice on bone formation by transplanted cells from normal and X-linked hypophosphataemic mice. J. Bone Miner. Res. 7 5 (1992) 523-530
27. Erben R.G., Mayer D., Weber K., Jonsson K., Juppner H., and Lanske B. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype. J. Bone Miner. Res. 20 (2005) 1149-1160 [Electronic publication 2005 Feb 21]
28. Fedarko N.S., Jain A., Karadag A., and Fisher L.W. Three small integrin-binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J. 18 (2004) 734-736
29. Francis F., Strom T.M., Hennig S., Boeddrich A., Lorenz B., Brandau O., et al. Genomic organisation of the human PEX gene mutated in X-linked dominant hypophosphataemic rickets. Gen. Res. 7 6 (1997) 573-585
30. Gowen L.C., Petersen D.N., Mansolf A.L., Qi H., Stock J.L., Tkalcevic G.T., et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J. Biol. Chem. 278 (2003) 1998-2007
31. Guo R., Liu S., Spurney R.F., and Quarles L.D. Analysis of recombinant Phex: an endopeptidase in search of a substrate. Am. J. Physiol. Endocrinol. Metab. 281 (2001) E837-E847
32. Guo R., Rowe P.S., Liu S., Simpson L.G., Xiao Z.S., and Quarles L.D. Inhibition of MEPE cleavage by Phex. Biochem. Biophys. Res. Commun. 297 (2002) 38-45
33. Gupta A., Tenenhouse H.S., Hoag H.M., Wang D., Khadeer M.A., Namba N., et al. Identification of the type II Na(+)-Pi cotransporter (Npt2) in the osteoclast and the skeletal phenotype of Npt2-/- mice. Bone 29 (2001) 467-476
34. Halstead L.R., Weinstein R.S., Cheng S.L., Rifas L., and Avioli L.V. Comparison of 22-oxacalcitriol and 1,25(OH)2D3 on bone metabolism in young X-linked hypophosphatemic male mice. Am. J. Physiol. 270 (1996) E141-E147
35. Harrell R.M., Lyles K.W., Harrelson J.M., Friedman N.E., and Drezner M.K. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J. Clin. Invest. 75 (1985) 1858-1868
36. Hruska K.A., Rifas L., Cheng S.L., Gupta A., Halstead L., and Avioli L. X-linked hypophosphatemic rickets and the murine Hyp homologue. Am. J. Physiol. 268 (1995) F357-F362
37. HYP-consortium, Francis F., Hennig S., Korn B., Reinhardt R., de Jong D., et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat. Genet. 11 (1995) 130-136
38. Imel E.A., and Econs M.J. Fibroblast growth factor 23: roles in health and disease. J. Am. Soc. Nephrol. 16 (2005) 2565-2575 [Electronic publication 2005 Jul 20]
39. Jain A., Fedarko N.S., Collins M.T., Gelman R., Ankrom M.A., Tayback M., et al. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J. Clin. Endocrinol. Metab. 89 (2004) 4158-4161
40. Jan de Beur S.M., Jain A., Khan M., and Fedarko N.S. Matrix extracellular phosphoglycoprotein (MEPE), fragments circulate in excess in patients with tumor-induced osteomalacia (TIO) and X-linked hypophosphatemic rickets (XLH). J. Bone Miner. Res. 19 (2004) F479 [(Abstract) S101]
41. Jo O.D., Shih R., Sun A., Pham P., Yanagawa J., and Yanagawa N. Cathepsin D (Cat D) and bone defect in hypophosphatemic (Hyp) mice [Abstract]. J. Am. Soc. Nephrol. 11 (2000) 408A
42. Matsumoto N., Jo O.D., Shih R.N.J., and Yanagawa N. Altered cathepsin D metabolism in Phex antisense human osteoblast cells. Biochem. Biophys. Res. Commun. 332 (2005) 248-253
43. Kornfeld S. Trafficking of lysosomal enzymes. FASEB J. 1 (1987) 462-468
44. Ling Y., Rios H.F., Myers E.R., Lu Y., Feng J.Q., and Boskey A.L. DMP1 Depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J. Bone Miner. Res. 20 (2005) 2169-2177 [Electronic publication 2005 Aug 22]
45. Liu S., Brown T.A., Zhou J., Xiao Z.S., Awad H., Guilak F., et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J. Am. Soc. Nephrol. 16 (2005) 1645-1653 [Electronic publication2005 Apr 20]
46. Liu S., Guo R., Simpson L.G., Xiao Z.S., Burnham C.E., and Quarles L.D. Regulation of FGF23 expression but not degradation by phex. J. Biol. Chem. 278 (2003) 37419-37426
47. Liu S., Guo R., Tu Q., and Quarles L.D. Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J. Biol. Chem. 277 (2002) 3686-3697
48. Lyles K.W., Harrelson J.M., and Drezner M.K. The efficacy of vitamin D2 and oral phosphorus therapy in X-linked hypophosphatemic rickets and osteomalacia. J. Clin. Endocrinol. Metab. 54 (1982) 307-315
49. Marie P.J., Travers R., and Glorieux F.H. Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse. Calcif. Tissue Int. 34 (1982) 158-164
50. Marie P.J., Travers R., and Glorieux F.H. Healing of bone lesions with 1,25-dihydroxyvitamin D3 in the young X-linked hypophosphataemic male mouse. Endocrinology 111 (1982) 904-911
51. Matsumoto N., Jo O.D., Shih R.N., Brochmann E.J., Murray S.S., Hong V., et al. Increased cathepsin D release by Hyp mouse osteoblast cells. Am. J. Physiol. Endocrinol. Metab. 289 (2005) E123-E132
52. Meng X.W., Liang X.G., Birchman R., Wu D.D., Dempster D.W., Lindsay R., et al. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J. Bone Miner. Res. 11 (1996) 421-429
53. Miao D., Bai X., Panda D., Karaplis A.C., Goltzman D., and McKee M.D. Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice. Bone 34 (2004) 638-647
54. Miao D., Bai X., Panda D., McKee M., Karaplis A., and Goltzman D. Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition. Endocrinology 142 (2001) 926-939
55. Murshed M., Harmey D., Millan J.L., McKee M.D., and Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev. 15 (2005) 15
56. Nesbitt T., Fujiwara I., Thomas R., Xiao Z.S., Quarles L.D., and Drezner M.K. Coordinated maturational regulation of PHEX and renal phosphate transport inhibitory activity: evidence for the pathophysiological role of PHEX in X-linked hypophosphatemia. J. Bone Miner. Res. 14 (1999) 2027-2035
57. Nishimura Y., Kawabata T., and Kato K. Identification of latent procathepsins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Arch. Biochem. Biophys. 261 (1988) 64-71
58. Ogawa T., Onishi T., Hayashibara T., Sakashita S., Okawa R., and Ooshima T. Dentinal defects in Hyp mice not caused by hypophosphatemia alone. Arch. Oral Biol. 7 (2005) 7
59. Ogbureke K.U., and Fisher L.W. Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int. 68 (2005) 155-166
60. Ono T., and Seino Y. Medical management and complications of X-linked hypophosphatemic vitamin D resistant rickets. Acta Paediatr. Jpn. 39 (1997) 503-507
61. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2 (1987) 595-610
62. Petersen D.N., Tkalcevic G.T., Mansolf A.L., Rivera-Gonzalez R., and Brown T.A. Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. J. Biol. Chem. 275 (2000) 36172-36180
63. Rifas L., Cheng S., Halstead L.R., Gupta A., Hruska K.A., and Avioli L.V. Skeletal casein kinase activity defect in the HYP mouse. Calcif. Tissue Int. 61 (1997) 256-259
64. Rifas L., Dawson L.L., Halstead L.R., Roberts M., and Avioli L.V. Phosphate transport in osteoblasts from normal and X-linked hypophosphatemic mice. Calcif. Tissue Int. 54 (1994) 505-510
65. Rifas L., Gupta A., Hruska K.A., and Avioli L.V. Altered osteoblast gluconeogenesis in X-linked hypophosphatemic mice is associated with a depressed intracellular pH. Calcif. Tissue Int. 57 (1995) 60-63
66. Rowe P.S. The molecular background to hypophosphataemic rickets. Arch. Dis. Child. 83 (2000) 192-194
67. Rowe P.S.N. The wrickkened-pathways of FGF23, MEPE and PHEX. Crit. Rev. Oral Biol. Med. 15 (2004) 264-281
68. Rowe P.S.N., de Zoysa P., Dong R., Wang H., White K., Econs M., et al. MEPE, a new gene expressed in bone-marrow and tumours causing osteomalacia. Genomics 67 1 (2000) 54-68
69. Rowe P.S.N., Garrett I.R., Schwarz P.M., Carnes D.L., Lafer E.M., Mundy G.R., et al. Surface plasmon resonance (SPR) confirms MEPE binds to PHEX via the MEPE-ASARM-motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36 (2005) 33-46
70. Rowe P.S.N., Goulding J.N., Francis F., Oudet C., Econs M.J., Hanauer A., et al. The gene for X-linked hypophosphataemic rickets maps to a 200-300 kb region in Xp22.1, and is located on a single YAC containing a putative vitamin D response element (VDRE). Hum. Genet. 97 (1996) 345-352
71. Rowe P.S.N., Kumagai Y., Gutierrez G., Garrett I.R., Blacher R., Rosen D., et al. MEPE has the properties of an osteoblastic Phosphatonin and Minhibin. Bone 34 (2004) 303-319
72. Rowe P.S.N., Ong A., Cockerill F., Goulding J., and Hewison M. Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphataemic osteomalacia. Bone 18 2 (1996) 159-169
73. Rowe P.S.N., Oudet C., Francis F., Sinding C., Pannetier S., Econs M.J., et al. Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum. Mol. Genet. 6 (1997) 539-549
74. Seufert J., Ebert K., Muller J., Eulert J., Hendrich C., Werner E., et al. Octreotide therapy for tumor-induced osteomalacia. N. Engl. J. Med. 345 (2001) 1883-1888
75. Sheehan D.C., and Hrapchak B.B. Theory and practice of histotechnology (1987), Battelle Press, Columbus
76. Shih N.R., Jo O.D., and Yanagawa N. Effects of PHEX antisense in human osteoblast cells. J. Am. Soc. Nephrol. 13 (2002) 394-399
77. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6500-6505
78. Shimada T., Muto T., Urakawa I., Yoneya T., Yamazaki Y., Okawa K., et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143 (2002) 3179-3182
79. Tenenhouse H.S., Gauthier C., Chau H., and St-Arnaud R. 1{alpha}-Hydroxylase gene ablation and Pi supplementation inhibit renal calcification in mice homozygous for the disrupted Na/Pi cotransporter gene Npt2a. Am. J. Physiol. Renal Physiol. 286 (2003) F675-F681
80. Tieder M., Modai D., Shaked U., Samuel R., Arie R., Halabe A., et al. "Idiopathic" hypercalciuria and hereditary hypophosphatemic rickets. Two phenotypical expressions of a common genetic defect. N. Engl. J. Med. 316 (1987) 125-129
81. van den Heuvel L., Op de Koul K., Knots E., Knoers N., and Monnens L. Autosomal recessive hypophosphataemic rickets with hypercalciuria is not caused by mutations in the type II renal sodium/phosphate cotransporter gene. Nephrol. Dial Transplant 16 (2001) 48-51
82. Weber T.J., Liu S., Indridason O.S., and Quarles L.D. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner. Res. 18 (2003) 1227-1234
83. White K.E., Evans W.E., O'Riordan J.L.H., Speer M.C., Econs M.J., Lorenz-Depiereux B., et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26 (2000) 345-348
84. Xiao Z.S., Crenshaw M., Guo R., Nesbitt T., Drezner M.K., and Quarles L.D. Intrinsic mineralization defect in Hyp mouse osteoblasts. Am. J. Physiol. 275 (1998) E700-E708
85. Yamamoto T., Ecarot B., and Glorieux F.H. Abnormal response of osteoblasts from Hyp mice to 1,25-Dihydroxyvitamin D3. Bone 13 (1992) 209-215
86. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87 (2002) 4957-4960
87. Ye L., Mishina Y., Chen D., Huang H., Dallas S.L., Dallas M.R., et al. Dmp1-deficient mice display severe defects in cartilage formation responsible for a chondrodysplasia-like phenotype. J. Biol. Chem. 280 (2005) 6197-6203 [Electronic publication 2004 Dec 7]
88. Yu X., and White K.E. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev. 16 (2005) 221-232 [Electronic publication 2005 Feb 5]